First Time Loading...
S

Shin Nippon Biomedical Laboratories Ltd
TSE:2395

Watchlist Manager
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Watchlist
Price: 1 416 JPY -3.34% Market Closed
Updated: May 15, 2024

Net Margin
Shin Nippon Biomedical Laboratories Ltd

20.6%
Current
29%
Average
1.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.6%
=
Net Income
5.5B
/
Revenue
26.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
59B JPY
21%
US
Thermo Fisher Scientific Inc
NYSE:TMO
231.8B USD
14%
US
Danaher Corp
NYSE:DHR
194.7B USD
18%
US
Agilent Technologies Inc
NYSE:A
45.1B USD
18%
US
IQVIA Holdings Inc
NYSE:IQV
42.5B USD
9%
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
23%
CH
Lonza Group AG
SIX:LONN
38.3B CHF
10%
US
Mettler-Toledo International Inc
NYSE:MTD
32.3B USD
21%
IE
ICON PLC
NASDAQ:ICLR
26.5B USD
8%
US
West Pharmaceutical Services Inc
NYSE:WST
25.6B USD
19%
US
Waters Corp
NYSE:WAT
21.3B USD
21%
S
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Country JP
Market Cap 59B JPY
Net Margin
21%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 231.8B USD
Net Margin
14%
Danaher Corp
NYSE:DHR
Country US
Market Cap 194.7B USD
Net Margin
18%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 45.1B USD
Net Margin
18%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 42.5B USD
Net Margin
9%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 55.6T KRW
Net Margin
23%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 38.3B CHF
Net Margin
10%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 32.3B USD
Net Margin
21%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.5B USD
Net Margin
8%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 25.6B USD
Net Margin
19%
Waters Corp
NYSE:WAT
Country US
Market Cap 21.3B USD
Net Margin
21%

Profitability Report

View the profitability report to see the full profitability analysis for Shin Nippon Biomedical Laboratories Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.6%
=
Net Income
5.5B
/
Revenue
26.7B
What is the Net Margin of Shin Nippon Biomedical Laboratories Ltd?

Based on Shin Nippon Biomedical Laboratories Ltd's most recent financial statements, the company has Net Margin of 20.6%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.